Cochrane · systematic review · CD011808
Inhaled nitric oxide for treating pain crises in people with sickle cell disease
Aboursheid, T, Albaroudi, O, Alahdab, F · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsInhaled nitric oxide compared with placebo for pain crises in people with sickle cell disease
Population: adults and children with SCD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to pain resolution Inhaled nitric oxide vs placebo | no estimate extracted | 1 study · 150 participants | Low Downgraded: risk of bias, imprecision |
Frequency of pain crises in the Inhaled nitric oxide vs placebo | RR 0.73 [0.31, 1.71] | 1 study · 150 participants | Low Downgraded: risk of bias, imprecision |
Frequency of pain crises in the Inhaled nitric oxide vs placebo | RR 0.53 [0.25, 1.11] | 1 study · 150 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Inhaled nitric oxide vs placebo | no estimate extracted | 1 study · 150 participants | Low Downgraded: risk of bias, imprecision |